Athira pharma presents preclinical data highlighting neuroprotective effects of ath-1105 in models of als at motor neurone disease association's 35th international symposium on als/mnd

Bothell, wash., dec. 06, 2024 (globe newswire) -- athira pharma, inc. (nasdaq: atha), a clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, today presented preclinical data highlighting target engagement and neuroprotective effects of ath-1105 in human motor neurons at the motor neurone disease association's 35th international symposium on als/mnd, taking place dec. 6-8, 2024, in montreal, canada.
ATHA Ratings Summary
ATHA Quant Ranking